Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:ANCHOR_trial
|
| gptkbp:activities |
HMG-Co A reductase inhibitor
|
| gptkbp:approves |
gptkb:1996
gptkb:FDA |
| gptkbp:brand |
gptkb:Lipitor
|
| gptkbp:clinical_trial |
Phase III
cardiovascular events cholesterol reduction primary prevention secondary prevention |
| gptkbp:contraindication |
pregnancy
breastfeeding active liver disease |
| gptkbp:current_use |
gptkb:Company
hypertension atherosclerosis coronary artery disease hyperlipidemia |
| gptkbp:dosage_form |
once daily
80 mg |
| gptkbp:excretion |
urine
bile |
| gptkbp:formulation |
oral tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
high-dose atorvastatin
|
| gptkbp:ingredients |
gptkb:atorvastatin
|
| gptkbp:interacts_with |
gptkb:HIV_protease_inhibitors
certain antibiotics antifungal medications |
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_monitored_by |
cholesterol levels
liver enzymes |
| gptkbp:is_used_for |
lowering cholesterol
|
| gptkbp:lifespan |
14 hours
|
| gptkbp:marketed_as |
multiple brand names
|
| gptkbp:pharmacokinetics |
highly protein-bound
|
| gptkbp:population |
adults
high-risk patients |
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
hyperlipidemia
ASCVD prevention high-intensity statin therapy |
| gptkbp:requires |
gptkb:theorem
|
| gptkbp:research_focus |
long-term effects
comparative effectiveness |
| gptkbp:scientific_classification |
gptkb:software
|
| gptkbp:side_effect |
fatigue
headache muscle pain liver damage rash gastrointestinal issues diabetes risk |
| gptkbp:storage |
room temperature
protected from moisture |